Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Control (functional) | = 84 % | Compound effect on the growth rate of L1210 murine leukemia cells at 10e-4 M concentration | ChEMBL. | 2913300 |
Control (functional) | = 84 % | Compound effect on the growth rate of L1210 murine leukemia cells at 10e-4 M concentration | ChEMBL. | 2913300 |
Cytotoxicity (functional) | > 100 uM | Cytotoxicity of compound in uninfected cells determined by examining the effect on growth of HFF cells | ChEMBL. | No reference |
Cytotoxicity (functional) | > 100 uM | Cytotoxicity of compound in uninfected cells determined by examining the effect on growth of HFF cells | ChEMBL. | No reference |
IC50 (ADMET) | > 0.0001 M | In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells | ChEMBL. | 2913300 |
IC50 (ADMET) | > 0.0001 M | In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells | ChEMBL. | 2913300 |
IC50 (functional) | > 100 uM | Antiviral activity of the compund was evaluated against the Herpes simplex virus type-1 in BSC-1 cells | ChEMBL. | 2913300 |
IC50 (ADMET) | > 100 uM | Cytotoxicity of the compound was evaluated against the Monkey kidney cells (BSC) | ChEMBL. | 2913300 |
IC50 (functional) | > 100 uM | In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay. | ChEMBL. | No reference |
IC50 (functional) | > 100 uM | In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay. | ChEMBL. | No reference |
IC50 (functional) | = 144 uM | Antiviral activity of the compund was evaluated against the Human cytomegalo virus (HCMV) | ChEMBL. | 2913300 |
IC50 (functional) | > 200 uM | Inhibitory activity against HIV in Alex cells | ChEMBL. | 2165163 |
IC50 (ADMET) | > 320 uM | Cytotoxicity of the compound was evaluated against the Human diploid cells (HFF) | ChEMBL. | 2913300 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.